Bacterial contamination of platelets is an important cause of transfusion-associated morbidity and mortality. It is currently the most frequent infectious complication of transfusion therapy, with between 1 in 1,000 and 1 in 3,000 platelet units being bacterially contaminated at time of transfusion. Several factors have contributed to the persistence of this problem including lack of sensitive detection methods, lack of recognition of the frequency of the problem, inadequate recognition of septic reactions by clinicians treating patients receiving platelet transfusions, differences in transfusion reactions between bacterial species and bacterial inocula transfused, and differing methodologies and time of testing for detection of bacteria in platelet units. There are also important correlations between the receipt of bacterially contaminated platelet units and the development of transfusion reactions and bacteremia. In the last few years the recognition of the importance of platelet bacterial contamination prompted the College of American Pathologists (CAP) and the American Association of Blood Banks (AABB) to set new standards requiring the screening of platelets for bacterial contamination. In the wake of these standards, an increasing number of approaches have been and are being developed to deal with this problem. The clinical sensitivity, specificity and predictive value of these detection methods vary considerably and need to be defined for routine laboratory practice. In this review, we focus on the practical aspects and feasibility of implementing FDA-cleared detection methods for identifying bacterially contaminated platelet units. We also present details of a number of methods under development for at-issue use.